Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 2
1980 1
1981 2
1982 1
1983 3
1985 1
1987 1
1989 1
1990 1
1991 1
1992 4
1993 1
1994 2
1995 4
1996 3
1997 4
1998 7
1999 12
2000 13
2001 14
2002 12
2003 20
2004 25
2005 24
2006 34
2007 54
2008 34
2009 56
2010 52
2011 64
2012 52
2013 54
2014 60
2015 58
2016 54
2017 52
2018 54
2019 44
2020 47
2021 57
2022 54
Text availability
Article attribute
Article type
Publication date

Search Results

915 results
Results by year
Filters applied: . Clear all
Page 1
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Kopetz S, et al. Among authors: hong ys. N Engl J Med. 2019 Oct 24;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30. N Engl J Med. 2019. PMID: 31566309 Clinical Trial.
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Tabernero J, et al. Among authors: hong ys. J Clin Oncol. 2021 Feb 1;39(4):273-284. doi: 10.1200/JCO.20.02088. J Clin Oncol. 2021. PMID: 33503393 Free PMC article. Clinical Trial.
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.
Yen I, Shanahan F, Lee J, Hong YS, Shin SJ, Moore AR, Sudhamsu J, Chang MT, Bae I, Dela Cruz D, Hunsaker T, Klijn C, Liau NPD, Lin E, Martin SE, Modrusan Z, Piskol R, Segal E, Venkatanarayan A, Ye X, Yin J, Zhang L, Kim JS, Lim HS, Kim KP, Kim YJ, Han HS, Lee SJ, Kim ST, Jung M, Hong YH, Noh YS, Choi M, Han O, Nowicka M, Srinivasan S, Yan Y, Kim TW, Malek S. Yen I, et al. Among authors: hong ys. Nature. 2021 Jun;594(7863):418-423. doi: 10.1038/s41586-021-03515-1. Epub 2021 May 5. Nature. 2021. PMID: 33953400 Clinical Trial.
Nigral MRI features of asymptomatic welders.
Lee EY, Flynn MR, Du G, Lewis MM, Goldenberg M, Kong L, Mailman RB, Hong YS, Huang X. Lee EY, et al. Among authors: hong ys. Parkinsonism Relat Disord. 2021 Apr;85:37-43. doi: 10.1016/j.parkreldis.2021.02.020. Epub 2021 Feb 24. Parkinsonism Relat Disord. 2021. PMID: 33691274 Free PMC article.
A Password Meter without Password Exposure.
Kim P, Lee Y, Hong YS, Kwon T. Kim P, et al. Among authors: hong ys. Sensors (Basel). 2021 Jan 6;21(2):345. doi: 10.3390/s21020345. Sensors (Basel). 2021. PMID: 33419094 Free PMC article.
Evaluation and management of lead exposure.
Kim HC, Jang TW, Chae HJ, Choi WJ, Ha MN, Ye BJ, Kim BG, Jeon MJ, Kim SY, Hong YS. Kim HC, et al. Among authors: hong ys. Ann Occup Environ Med. 2015 Dec 15;27:30. doi: 10.1186/s40557-015-0085-9. eCollection 2015. Ann Occup Environ Med. 2015. PMID: 26677413 Free PMC article. Review.
Methylmercury exposure and health effects.
Hong YS, Kim YM, Lee KE. Hong YS, et al. J Prev Med Public Health. 2012 Nov;45(6):353-63. doi: 10.3961/jpmph.2012.45.6.353. Epub 2012 Nov 29. J Prev Med Public Health. 2012. PMID: 23230465 Free PMC article. Review.
915 results